Analytical validation of the Altera tumor genomic profiling test

Performance of the Empower Hereditary Cancer Test

Seeing beyond the limit: Detect residual disease and assess treatment response

Summary of analytical and clinical data for Signatera™, the first ctDNA assay custom-built for MRD detection and treatment response.

Detecting molecular residual disease with Signatera

Design and analytical validation of SignateraTM, the first ctDNA assay custom-built for detecting MRD and assessing treatment response.